Indegene’s Kay Uttech was awarded the Engagement Achievement Award by the Healthcare Businesswomen’s Association (HBA) for her contribution for promoting gender parity in the industry in 2021.
The award recognizes an individual who has demonstrated consistent leadership that positively impacted member engagement, fostered collaboration, and promoted overall excellence in furthering the HBA mission.
HBA, whose mission is to help achieve gender parity in leadership positions in healthcare, facilitate business and connections and help organizations realize the full potential of their female talent, recognized Uttech for her exemplary role in supporting this goal and bringing in lot more engaged members to the organization.
Uttech began her role on the HBA Southeast Regional Council as a Membership and Engagement Regional Director. In that role, she streamlined the volunteer and award process so that the regional council members could traverse the process seamlessly.
Uttech, who is currently is Vice President, Strategic Initiatives, at Indegene, said, “I want to thank the amazing team in the SE region and the HBA home office who have been instrumental in ensuring that members are connected to HBA and the volunteer opportunities available that can help them advance their career.”
Indegene is a technology-led healthcare solutions provider, combining industry expertise with fit-for-purpose technology in an agile and scalable operating model.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.